BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 27, 2020
View Archived Issues
SARS-CoV-2 requires ACE2 and TMPRSS2 for cell entry, which may be blocked by a TMPRSS2 inhibitor
Read More
Mitochondria-related miR-4485-3p is underexpressed in idiopathic asthenozoospermia
Read More
ChAdOx1 nCoV-19 vaccine candidate enters clinical testing
Read More
Oryzon to initiate phase II ESCAPE study of vafidemstat in severely ill COVID-19 patients in Spain
Read More
Promising data for COVID-19 patients with ARDS treated with remestemcel-L
Read More
MMP12 as a novel target for post-stroke neurological recovery
Read More
TNIK is a novel druggable target in LSCC with 3q amplification
Read More
Edited stem cells reverse mouse diabetes
Read More
Noncoding TET2 variants affect neurodegeneration risk
Read More
Ichnos Sciences describes new MAP4K1 inhibitors
Read More
New menin/MLL interaction inhibitors patented by University of Michigan, Agios Pharmaceuticals
Read More
Genentech, Roche present IL-2 secretion inducers
Read More
SiteOne Therapeutics identifies Nav1.7 channel blockers
Read More
Sloan-Kettering Institute for Cancer Research, Tri-I TDI identify PI3K-alpha inhibitors
Read More
Flu study links metabolic changes to cytokine storm
Read More
AGTR1 and aromatase are potential therapeutic targets in glioblastoma
Read More
SAGE-324 generally well tolerated in essential tremor patients, phase II study planned
Read More
Polyneuron receives European clearances for phase I/IIa study of PN-1007 in anti-MAG neuropathy
Read More
Lilly begins phase II study of LY-3127804 in COVID-19
Read More
Hyundai studies BPDO-1603 in phase III for moderate to severe Alzheimer's disease
Read More
Hua reports phase I data on dorzagliatin with empagliflozin in type 2 diabetes
Read More
Phase III study of Libtayo in first-line NSCLC meets OS primary endpoint
Read More
Avadel reports pivotal phase III data on FT-218 in patients with narcolepsy
Read More
New phase III trial to evaluate pacritinib in patients with severe COVID-19
Read More
Preliminary findings from phase II portion of U.S. phase II/III trial of Kevzara in COVID-19
Read More